PAUL KLAVERWEIDEN: Open Payments
NPI 1760984454 · FRUITLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,538 in 82 payments from 17 companies in 2025. Trend: 2023 $5,321 · 2024 $900 · 2025 $1,538
Food & beverage: $1,538
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $169 |
| ABBVIE INC. | 11 | $154 |
| Vanda Pharmaceuticals Inc. | 7 | $146 |
| Axsome Therapeutics, Inc. | 6 | $124 |
| Alkermes, Inc. | 6 | $121 |
| Supernus Pharmaceuticals, Inc. | 5 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $95 |
| Neurocrine BioSciences, Inc. | 4 | $87 |
| IDORSIA PHARMACEUTICALS US INC | 4 | $81 |
Products named: CAPLYTA, VRAYLAR, Auvelity, ARISTADA, Qelbree, REXULTI, COBENFY, UZEDY.
Industry payments across MD — which companies pay providers there.
